Australia’s DoH seeks feedback on biosimilars awareness project

Biosimilares/General | Posted 16/10/2015 post-comment0 Post your comment

Australia’s Department of Health (DoH) wants to improve awareness and confidence in biosimilars in the community and among healthcare professionals, including pharmacists and prescribers. To do this the DoH has developed an implementation framework, for which it is seeking feedback.

Question-Fimea-V15E29

The implementation framework has been developed as part of the measures foreseen in the Pharmaceutical Benefits Scheme (PBS)* Access and Sustainability Package, including the Sixth Community Pharmacy Agreement (6CPA). This includes measures to support the use and awareness of biosimilars and ensure appropriate policies can be applied to provide market access and increase consumer choice and access and achieve the savings that can be gained from the use of these products.

The DoH is seeking stakeholder feedback on the framework via an online survey on the following:

  • Understanding of the Australian system
  • Position on biosimilars
  • Communication issues/risks
  • Key messages for prescribers, pharmacists and consumers
  • What communication channels stakeholders currently use to communicate and recommendations about their effectiveness
  • Willingness to assist with the distribution of communication materials about biosimilars

The Australian Government is investing AUS$20 million during 2015–2018 for awareness activities designed to improve awareness and confidence in biosimilars, for both healthcare professionals and consumers.

Stakeholders can provide feedback on the implementation framework and participate in the survey regarding biosimilars use in Australia by completing the online survey (Seeking feedback on Biosimilar Awareness Implementation Framework) at www.consultations.health.gov.au/pharmaceutical-policy-branch/biosimilar-implementation-framework. The survey will be accessible until 26 October 2015.

*The Pharmaceutical Benefits Scheme (PBS) is a programme of the Australian Government that provides subsidized prescription drugs to residents of Australia.

Related articles
Australia’s PBAC recommends substitution of biosimilars

Australian government urged not to make further cuts to PBS

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved. 

Source: PBS

comment icon Comments (0)
Post your comment
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010